Hormonal
GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes, particularly those with established cardiovascular disease.
If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like liraglutide or semaglutide) are proven to significantly lower your risk of heart attack, stroke, and death. This benefit exists alongside blood sugar control. However, if you have heart failure with reduced ejection fraction, these drugs may increase risks, so discuss your specific heart condition with your doctor before starting.
Multi-country, multi-center long-term cardiovascular outcome trials (CVOTs) confirmed that GLP-1RAs decrease cardiovascular mortality and provide cardiovascular benefits to reduce the incidence of MI or non-fatal stroke [3]. For example, in the LEADER trial, when compared with placebo, liraglutide decreased the incidence of major cardiovascular events by 13%, cardiovascular death by 22% and all-cause death by 15% among T2DM patients with CVD, on a standard treatment basis [4].
Why this rating
Based on multiple large-scale, multi-center, long-term cardiovascular outcome trials (CVOTs) including LEADER, SUSTAIN-6, and REWIND.
Source
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Xiaoxuan Ma et al. · International Journal of Biological Sciences · 2021
DOI 10.7150/ijbs.59965
More from this paper
- GLP-1 receptor agonists reduce blood pressure and improve lipid profiles (LDL-C, triglycerides), contributing to the stabilization of atherosclerotic plaques and reduced cardiovascular risk.Good
- GLP-1 receptor agonists exhibit protective effects on the kidneys by reducing the decline in estimated glomerular filtration rate (eGFR) and delaying the onset of proteinuria in patients with Type 2 Diabetes.Good
- GLP-1 receptor agonists may increase the risk of adverse heart failure outcomes in patients with heart failure and reduced left ventricular ejection fraction (LVEF), despite showing cardiovascular benefits in other populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →